Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-05

Clinical Trial Update: Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating regorafenib after sorafenib in hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Regorafenib (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED | Results posted: 2017-06-05